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The differentiation betweenmultiple system atrophy (MSA) and Parkinson’s disease (PD) is
difficult, particularly in early disease stages. Therefore, we aimed to evaluate the diagnostic
value of neurofilament light chain (NFL), fms-like tyrosine kinase ligand (FLT3L), and total
tau protein (t-tau) in cerebrospinal fluid (CSF) as biomarkers to discriminate MSA from
PD. Using commercially available enzyme-linked immunosorbent assays, we measured
CSF levels of NFL, FLT3L, and t-tau in a discovery cohort of 36 PD patients, 27 MSA
patients, and 57 non-neurological controls and in a validation cohort of 32 PD patients,
25 MSA patients, 15 PSP patients, 5 CBS patients, and 56 non-neurological controls.
Cut-offs obtained from individual assays and binary logistic regression models developed
from combinations of biomarkers were assessed. CSF levels of NFL were substantially
increased in MSA and discriminated between MSA and PD with a sensitivity of 74% and
specificity of 92% (AUC=0.85) in the discovery cohort and with 80% sensitivity and 97%
specificity (AUC=0.94) in the validation cohort. FLT3L levels in CSF were significantly
lower in both PD and MSA compared to controls in the discovery cohort, but not in
the validation cohort. t-tau levels were significantly higher in MSA than PD and controls.
Addition of either FLT3L or t-tau to NFL did not improve discrimination of PD from MSA
above NFL alone. Our findings show that increased levels of NFL in CSF offer clinically
relevant, high accuracy discrimination between PD and MSA.
Keywords: Parkinson’s disease, multiple system atrophy, neurofilament light chain, FLT3 ligand, cerebrospinal fluid
Introduction
Parkinson’s disease (PD) is the most common movement disorder with typical age of onset around
60 years although some patients (~3–5%) develop PD before the age of 40 (1). PD is characterized
by four cardinal motor features: involuntary tremor, postural instability, bradykinesia, and rigidity
(2). Non-motor features such as cognitive disturbances, depression, mild autonomic dysfunction
(including orthostatic hypotension), and disordered sleep commonly accompany these motor
symptoms (3).
Multiple system atrophy (MSA) is a relatively rare and sporadic adult-onset disease characterized
by a variable combination of parkinsonism, cerebellar ataxia, autonomic dysfunction (particularly
orthostatic hypotension), and pyramidal signs (4). MSA is commonly misdiagnosed as PD, partic-
ularly in early disease stages, because of overlapping symptoms, occasionally good responsiveness
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to dopaminergic treatment in MSA, and similar age of onset,
typically around 60 years (1, 4). However, MSA progresses more
rapidly thanPDand is associatedwith amuchpoorer quality of life
(5). Moreover, the response to levodopa, although variable, is gen-
erally poor and may lead to worsening of orthostatic hypotension
in some MSA patients (6). A reliable biomarker capable of clearly
distinguishing betweenMSAandPDwould have great clinical and
diagnostic value.
Two recent studies have investigated the utility of fms-like tyro-
sine kinase ligand (FLT3L) as a potential cerebrospinal fluid (CSF)
biomarker to differentiate MSA from PD but had conflicting
results. While one paper reported that CSF levels of FLT3L could
differentiate betweenMSA and PDwith high accuracy (7) another
showed no significant differences in FLT3L levels between MSA
and PD (8). However, there is currently no literature available
investigating the biological significance of FLT3L in PD. There-
fore, additional studies are required to ascertain the utility of
FLT3L as a biomarker and, if its utility in distinguishing PD from
MSA can be confirmed, further studies investigating its biological
significance would be highly warranted.
Neurofilament proteins are highly phosphorylated neuronal
cytoskeleleton proteins composed of three subunits of which the
smallest, the 68 kDa neurofilament light chain (NFL), forms the
backbone and is essential for neurofilament assembly (9). Ele-
vated levels of CSF NFL in atypical parkinsonisms compared
with PD and controls have been observed and may reflect more
extensive neuronal damage in AP than in PD. Similarly, tau
has an important function in providing structural stability to
axonal microtubules. Mutations in the MAPT gene have been
associated with PD and thus mark tau as a potential biomarker
for PD (10). As might be expected, CSF levels of NFL and
total tau protein (t-tau) have been shown to discriminate PD
from atypical parkinsonisms (11–14) but these studies require
further validation. In the current study, we aimed to determine
which CSF biomarker (NFL, t-tau, or FLT3L), or combination
of biomarkers, could provide optimal discrimination of MSA
from PD.
Materials and Methods
Patients
The present studywas performed at the RadboudUniversityMed-
ical Centre (Nijmegen, the Netherlands). We studied patients ini-
tially referred to our tertiary movement disorder center between
December 2000 and November 2008 (Figure 1), with a hypoki-
netic rigid syndrome of uncertain diagnosis at presentation, and
who received a subsequent diagnosis of PD or MSA. The initial
clinical diagnosis (at presentation) was established by a neurol-
ogist specialized in movement disorders according to current
diagnostic criteria for PD (15) and MSA (16). Patients underwent
extensive neurological examination and a subset of the patients
were included from a previous study in which they were studied
prospectively for three years (57% of MSA and 86.8% of PD
patients) (17). For these patients, diagnosis was established by
FIGURE 1 | Flowchart of patient inclusion in this study. PD, Parkinson’s disease; MSA, multiple system atrophy; PSP, progressive supranuclear palsy; CBD,
corticobasal degeneration; CSF, cerebrospinal fluid; n, number. CSF was obtained during the initial diagnostic assessment upon presentation.
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two neurologists specialized in movement disorders and patients
underwent extensive neurological examination and imaging stud-
ies at initial visit and again after 3 years (SupplementaryMaterial).
Ten MSA patients and five PD patients have been described
earlier (14, 18) but the CSF parameters reported in the current
study were not previously reported. The remaining eight MSA
and four PD patients were incidental cases for whom case review
follow-up was performed by a neurologist (author Marjolein
B. Aerts).
Disease severity was established using the (modified) Hoehn
and Yahr (H&Y) (19) stages and unified Parkinson’s disease rat-
ing scale (UPDRS) (20); ataxia severity was assessed using the
International Cooperative Ataxia Rating Scale (ICARS) (21). Final
diagnosis was confirmed by case review up to 9 years after initial
visit. Controls consisted of patients referred to our Neurology
Department during the period 2001–2009, who underwent lum-
bar puncture as part of the diagnostic process, and who had been
confirmed as having no neurological disease.
For the discovery group, we analyzedCSF samples fromPD and
MSA patients obtained between 2001 and 2004, and controls con-
sisted of patients with lumbar punctures obtained between 2001
and 2006. To validate our findings, we examinedCSF in additional
MSA and PD patients with lumbar punctures obtained between
2005 and 2008, and control CSFs obtained between 2007 and
2010. Additional patients diagnosed with progressive supranu-
clear palsy (PSP, n= 15) and corticobasal syndrome (CBS, n= 5)
with previously unreported, retrospective CSF NFL levels were
included to show differences in NFL levels between PD patients
and other atypical parkinsonisms (Figure 1; Table S5 in Sup-
plementary Material). Initial clinical diagnosis for these patients
was established by a movement disorders specialist using current
diagnostic criteria for PSP (22) and CBS (23). Lumbar puncture
samples from all MSA and PD patients were analyzed for all CSF
parameters to determine and validate the utility of these param-
eters in discriminating PD from MSA. Controls in the discovery
group were tested for all CSF parameters for comparison with PD
and MSA patients. NFL and FLT3L levels in a second group of
controls in the validation cohort provided additional reference
values for these parameters.
Ethical Statement
The following applies to 59/68 PD patients and 32/52 MSA
patients: written informed consent was obtained from the par-
ticipants prior to participation of the study. All clinical investiga-
tions have been conducted according to the principles expressed
in the Declaration of Helsinki. In case patients were unable to
consent (defined as MMSE score below 25), written informed
consent was obtained from a next of kin of the patient. The local
institutional review board (“Commissie Mensgebonden Onder-
zoek region Arnhem-Nijmegen”) approved of this study. For the
remaining patients (i.e., 9/68 of PD patients, 20/52 MSA patients,
and all controls), CSF samples were obtained as part of the clinical
diagnostic work-up of a patient. Patients were informed that their
data, including CSF, could be used for further scientific purposes
and were given the option to object against this use, in which
case their data were not used. This procedure has been approved
as well.
CSF Samples and Analysis
Cerebrospinal fluid samples obtained by lumbar puncture were
collected in polypropylene tubes, centrifuged (5min, 860 g
at room temperature), and stored at  80°C. Patient informa-
tion was decoded to maintain confidentiality. Undiluted CSF
samples were measured in duplicate using commercially avail-
able enzyme-linked immunosorbent assays (ELISAs) for Human
FLT3L (R&D Systems, Abingdon, UK), NFL (NF-light® Neuro-
filament ELISA RUO; a gift from UmanDiagnostics, Sweden),
and t-tau (INNOTEST® hTau, InnogeneticsN.V., Ghent, Belgium).
ELISAs were performed according to manufacturer’s instructions
except the capture antibody for the FLT3L ELISA was used at
1 µg/mL.
Statistical Analysis
Cerebrospinal fluid parameters with non-Gaussian distribution
were log transformed and between-group differences were tested
using one-way analysis of variance (ANOVA) followed by Tukey’s
post hoc test. Mann–Whitney U tests were used to compare data
with a non-Gaussian distribution (NFL levels in the discovery
group). Spearman rank correlation was used to determine cor-
relations. We performed analysis of covariance (ANCOVA) to
control for possible confounding variables (e.g., age, gender, dis-
ease duration, and disease severity). Binary logistic regression
was used to identify variables contributing to discrimination of
MSA from PD and receiver–operator curves (ROCs) were used to
determine the diagnostic accuracy of CSF parameters and models
developed from the binary logistic regression. Statistical analyses
were performed using GraphPad PRISM 5 software (San Diego,
CA, USA) and SPSS software version 20.0 (Chicago, IL, USA).
Comparison of the ROC curves was performed using MedCalc®
software version 12.5.0.0. Bootstrapping analyses using data from
both cohorts were also performed for additional validation of the
measures using Medcalc 12.7.0 9 Trial version.
Results
Patient Characteristics
We analyzed 233 CSF samples: 52 MSA patients, 68 PD patients,
and 113 non-neurological controls. Of these, 61% (32/52) of
the MSA and 87% (59/68) of the PD patients had been studied
prospectively for 3 years. The discovery group consisted of 36 PD,
27MSA, and 57 controls. Patient characteristics and CSF parame-
ters are reported in Table 1. CSF samples from controls were used
to obtain reference values for NFL, FLT3L, and t-tau. In order
to confirm the use of NFL, FLT3L, and t-tau in discriminating
between PD and MSA, we included a validation group consisting
of 32 PD and 25 MSA patients. Since CSF measures of NFL and
FLT3L are rather novel, we included 56 additional controls to
obtain additional reference values.
NFL, t-tau, and FLT3L Levels in CSF of the
Discovery Cohort
In the discovery group, CSF FLT3L levels were significantly lower
in PD (38.4 11.9 ng/L; p< 0.01) and MSA (39.3 12.4 ng/L;
p< 0.05) compared with controls (47.8 14.3 ng/L) but similar in
MSA and PD (Figure 2A). We found significantly higher levels
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TABLE 1 | Patient demographic and baseline characteristics – discovery
cohort.
PD (n= 36) MSA (n= 27) Controls
(n= 57)
Age in years (SD)b 60.1 (10.4) 62.6 (9.0) 57.0 (11.5)
Number of males (%) 22 (61.1) 15 (55.6) 37 (64.9)
Years of follow-up
(range)
5.5 (0–9.2) 2.9 (0–7.9) N/A
NFL (ng/L) 1350 (915) 4548 (3206) 1503 (619)
FLT3L (ng/L) 38.4 (11.9) 39.3 (12.4) 47.8 (14.3)
t-tau (ng/L) 242 (190) 335 (164) 251 (110)
Disease duration,
months (range)c
PD (n= 28) MSA (n= 14) p-Valuea
43.8 (6–158) 43.7 (8–96) p= 0.508
Disease severityc PD (n= 32) MSA (n= 14) p-Valuea
H&Y 2.0 (0.60); n= 32 2.7 (1.2); n= 14 p= 0.014
UPDRS; mean (SD) 30.3 (11.5); n= 27 32.5 (16.7); n= 14 p= 0.627
ICARS; mean (SD) 2.9 (4.8); n=20 12.1 (9.5); n= 9 p= 0.020
Cognitive function PD (n= 28) MSA (n= 14) p-Valuea
MMSE; mean (SD) 28.5 (1.6) 27.5 (3.5) p>0.05
SD, standard deviation; H&Y, Hoehn and Yahr score; ICARS, International Cooperative
Ataxia Rating Scale; UPDRS, unified Parkinson’s disease rating scale; N/A, not applicable.
aStudent’s t-test p-values for PD versus MSA.
bAt time of lumbar puncture.
cAt time of inclusion.
of CSF NFL in MSA (4548 3206 ng/L) compared with both
PD (1350 915 ng/L, p< 0.001) and controls (1503 619 ng/L,
p< 0.001) but not between PD and controls (Figure 2B). CSF t-
tau levels were significantly higher forMSA (335 164 ng/L) than
PD (242 190 ng/L; p< 0.05; Figure 2C) and, compared with our
reference values for t-tau in healthy controls, 46% ofMSA patients
and 11% of PD patients had elevated (350 ng/L) t-tau levels.
FLT3L correlated with both NFL and t-tau for PD and controls
but notMSA. There was a moderate correlation between NFL and
t-tau in PD (r= 0.39, p< 0.05) but not MSA (r= 0.34, p= 0.11)
or controls (r= 0.43, p= 0.08). Details of the correlation data are
provided in Table S1 in Supplementary Material. Four of the PD
patients exhibited levels of t-tau that weremarkedly different from
the remainder of the group (Figure 2C) but this was not correlated
with MMSE since individual MMSE scores were 30 for 1 patient,
29 for 2 patients, and 26 for 1 patient. Despite long-term clinical
follow-up (3–8.8 years), we can neither rule out, nor confirm,
subclinical tauopathy in these patients.
Neurofilament light chain alone provided high discrimination
(AUC 0.85) between MSA and PD with 74.1% sensitivity and
91.7% specificity. Logistic regression models of combination
biomarkers were then analyzed (summarized in Table 2). The
combination of t-tau and NFL developed in our previous study
(12) (Model 1: y=NFL+ 0.15*t-tau; AUC= 0.89) yielded
similar sensitivity (75.0%) and specificity (91.2%; AUC= 0.90)
for discriminating MSA from PD whereas the combination
of FLT3L and NFL (Model 2: y= 1.646+ 0.001*NFL-
0.0308*FLT3L) yielded a sensitivity of 81.8% and specificity of
94.8% (AUC= 0.89). The combination of NFL, FLT3L, and t-tau
(Model 3: y= 3.054–0.001*NFL+ 0.003*t-tau  0.028*FLT3L)
yielded a higher AUC (0.92) with increased sensitivity (94.7%)
but reduced specificity (83.3%). Comparison of the ROC analyses
showed that this improvement was not significantly better at
discriminating betweenMSA from PD thanNFL alone (p> 0.05).
Gender was not correlated with CSF parameters for any group.
Age was correlated with, or tended to be correlated with, all CSF
parameters in PD and controls but not in MSA (Table S2 in
Supplementary Material). Disease duration and severity (ICARS
and H&Y) were not correlated with CSF parameters for either
PD or MSA in the discovery cohort. UPDRS was not correlated
with CSF parameters in the PD group but, intriguingly, showed a
significant negative correlation with NFL (r= 0.57, p< 0.05) in
MSA.Details of these correlations are provided in Table S3 in Sup-
plementary Material. When we repeated our analyses controlling
for age, gender, UPDRS, and disease duration using ANCOVA,
significance levels were maintained for NFL but not FLT3L or
t-tau, suggesting that NFL levels are robust but FLT3L and t-
tau levels may be influenced by other factors that give rise to
heterogeneous values.
Validation of the Diagnostic Markers
In the validation cohort, we confirmed higher levels of CSF NFL
in MSA (5938 4267 ng/L) compared with PD (1103 442 ng/L;
p< 0.001) and controls (1290 664 ng/L; p< 0.001; Table S4 in
Supplementary Material). CSF NFL levels were also significantly
higher in other atypical parkinsonsisms (AP; 15 PSP and 5 CBS)
than in PD and controls (Table S5 in Supplementary Material).
This significance was maintained after controlling for age, gender,
and disease durationwithAUC 0.9 (Figure S1 in Supplementary
Material). FLT3L levels were non-significantly lower in both PD
andMSA compared with the controls although a small significant
difference between MSA and controls was found after controlling
for age, gender, disease duration, and disease severity (p< 0.05).
As with the discovery group, we also observed higher levels of t-
tau inMSA than PDbut this failed to reach significance (p= 0.06).
We noted that t-tau levels in both PD and MSA in the validation
groups were overall lower than in the discovery group and for
MSA the difference in t-tau levels in discovery (335 164 ng/L)
versus validation (244 93 ng/L) was significant (p< 0.05). The
methodology used to measure t-tau (Innotest ELISAs) was the
same for all patients but CSF samples collected prior to 2004 were
analyzed retrospectively, which may have influenced our results.
Disease duration was significantly shorter in PD (25.1months;
range 6–84) thanMSA (39.0months; range 12–106) in the valida-
tion group, but controlling for this variable using ANCOVA did
not alter the significance level for the CSF parameters.
The models developed using the CSF parameters from the
discovery group were applied to the validation group and diag-
nostic values were calculated using cut-offs obtained from the
discovery group. We could correctly identify the majority of
MSA patients (sensitivity= 80% and specificity= 97%) using
NFL alone (AUC= 0.94). Again, ROC curve comparison showed
that none of the models significantly improved the discrimination
of MSA from PD.
Bootstrapping analysis of the combined data to further validate
our result, produced an ROC curve for NFL (PD versus MSA)
that was highly comparable with ROC curves from the individual
cohorts (AUC= 0.90; sensitivity= 77%; specificity= 96%, cut-off
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FIGURE 2 | Cerebrospinal fluid concentrations of FLT3L, NFL, and t-tau
for the MSA, PD, and control groups: discovery cohort. (A) FLT3L levels
are significantly reduced in MSA and PD as compared to controls. NFL (B) and
t-tau (C) concentrations are significantly increased in the MSA group compared
with the PD group. MSA, multiple system atrophy; PD, Parkinson’s disease; NS,
non-significant difference; mean values are indicated by horizontal lines.
TABLE 2 | Comparison of models for discriminating MSA from PD.
CSF variables Number of patientsa Cut-off b point Sensitivity (%) Specificity (%) AUC Youden indexc Likelihood ratiod
DISCOVERY
NFL PD= 36, MSA= 27 >2315 74.1 91.7 0.854 65.7 8.9
Model 1e PD= 34, MSA= 20 >2388 75.0 91.2 0.879 70.6 8.5
Model 2f PD= 31, MSA= 22 > 0. 925 81.8 94.8 0.887 68.9 6.3
Model 3g PD= 29, MSA= 15 > 1.604 94.7 83.3 0.921 78.1 5.7
VALIDATION
NFL PD= 32, MSA= 25 >2315 80.0 96.9 0.938 76.9 25.6
Model 1e PD= 32, MSA= 24 >2388 76.1 96.9 0.932 76.1 25.3
Model 2f PD= 32, MSA= 23 > 0. 925 82.6 96.9 0.969 79.5 26.4
Model 3g PD= 32, MSA= 22 > 1.604 81.8 96.9 0.948 75.6 26.2
aDue to missing data points, not all CSF parameters were available in all patients.
bCut-off refers to the selected value of the individual biomarker or the combination where the two groups can be separated at the indicated sensitivity and specificity.
cYouden index: sensitivity+ specificity 100.
dLikelihood ratio: sensitivity/(1  specificity).
eModel 1: y=NFL+0.15*t-tau.
fModel 2: y= 1.646+0.001*NFL-0.03*FLT3L.
gModel 3: y= 3.054–0.001*NFL+0.003*t-tau  0.028*FLT3L.
>2174 ng/L). Bootstrapping of the combined FLT3L data revealed
significantly lower levels of FLT3L in both the PD and MSA
groups compared with controls as was observed in the discovery
group but not the validation group. We found no significant
differences in CSF FLT3L levels between PD and MSA patients
in the individual cohorts nor when using bootstrapping of the
combined data.
Discussion
In the current study, we showed that CSF levels of NFL can be
used for clinically relevant discrimination ofMSA fromPD. These
results confirm our previous findings using a different method
of detection for NFL (14) and the findings of a more recent
study using the same ELISA method (12). However, unlike these
previous case-control studies, we recruited most of our patients
from a prospective studywith long clinical follow-up. Higher t-tau
levels for MSA patients in this study confirm similar observation
in other studies (12, 14, 18) but the contribution of t-tau to the
overall discrimination of PD from MSA was not significant. We
noted high t-tau values in around 11% of our PD patients and
46% of our MSA patients in the discovery group. However, very
few patients in the validation group had high t-tau levels (3% of
PD and 8% of MSA). Since the diagnostic value of our previously
developed model combining NFL and t-tau (Model 1), did not
differ between the discovery and validation groups, this variation
probably did not adversely influence our results.
We found significantly decreased CSF FLT3L levels in PD and
MSA compared to controls in our discovery cohort but not in
the validation cohort. Bootstrapping of the combined data was
consistent with the discovery group, revealing significantly lower
levels of FLT3L in both PD and MSA compared with controls
but we and others (10) found no significant differences in CSF
FLT3L levels between PD and MSA. These results contradict an
earlier study showing high accuracy discrimination between PD
and MSA using FLT3L but we have used a different method of
detection for FLT3L than the original paper (7) and our results
agree with a more recent study using the same methodology as
the original paper (9).
Unlike the first study (7), we did not attempt to exclude patients
with possible familial PD, although genetic causes of PD were not
identified in our cohorts. Variance could be partly attributable to
inclusion of younger PD patients (<50 years in 15/52 PD patients)
since we observed a strong correlation between age and FLT3L
levels in both PD and controls. After subdivision of PD and MSA
for age (i.e.,>50 and<50 years), differences betweenPDandMSA
were maintained and we found no differences between young
versus old PD or MSA patients (data not shown).
Neurofilament proteins are essential for maintaining the neu-
ronal cytoskeleton and increased levels of NFL in the CSF of
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MSA patients likely reflects extensive axonal degeneration. In
keeping with earlier findings (12, 14), CSF NFL was increased
in MSA and aided discrimination of MSA from PD and, in the
current study, NFL alone provided the best tool for discriminating
between MSA and PD. The addition of FLT3L and t-tau to NFL
analysis improved this discrimination only slightly. However, we
observed strong correlations between NFL and FLT3L in PD
and controls in both the discovery and validation phases that
warrant further investigation to determine the potential func-
tion of FLT3L in the central nervous system. The lack of cor-
relation between NFL and FLT3L in the MSA patients suggests
that increased levels of NFL were not dependent on changes in
FLT3L or vice versa and does not support a role for FLT3L in the
pathology of MSA.
FLT3L is a hematopoietic growth factor expressed in various
tissues including the brain (24) and has an important role in
hematopoietic stem cell survival and proliferation (25). Although
FLT3L has a neurotrophic function contributing to increased
survival of a subset of post-mitotic neurons (24), its role in
neurodegenerative diseases is unknown. In amyotrophic lateral
sclerosis (ALS), CSF levels of FLT3L are elevated compared with
healthy controls (26). Nerve growth factor (NGF), which nor-
mally synergizes with FLT3L to exert its neurotrophic effect,
also increases the expression of NFL. Since both NGF and NFL
are increased in ALS (27, 28), NGF may contribute to elevated
levels of FLT3L and NFL as observed in ALS (27, 29, 30). In
PD, levels of NGF are reduced (29) and possibly contribute
to observed reductions in CSF FLT3L and NFL levels in some
patients. However, contrary to previous observations, CSF FLT3L
levels alone do not serve as a biomarker for differentiation ofMSA
from PD.
A major strength of our study is that diagnosis was made
prospectively for the majority of PD and MSA patients using
detailed neurological examination in combination with imaging
studies, and final diagnosis was confirmed after long follow-up
by case review. Our findings emphasize a consistency with other
studies (12–14, 31) showing that CSF NFL levels could be a useful
adjunct to clinical diagnosis for distinguishing PD from MSA
and other atypical parkinsonisms. Since both ours and previous
studies have shown significantly increased CSF NFL levels in
atypical parkinsonism disorders other than MSA, including PSP
and CBS (12, 13, 31), CSF NFL levels do not represent a specific
marker for MSA but rather, may be more generally useful for dis-
tinguishing PD from atypical parkinsonisms (12, 14). Our results
will require confirmation in larger cohorts in future research,
with (eventual) pathological confirmation of disease. Further,
additional studies will also be required to determine whether NFL
levels are influenced by other extraneous influences such as other
non-neurological diseases (e.g., cancer) (32, 33) or familial versus
sporadic forms of PD, and to determine whether increased NFL
levels will be useful for differentiating PD from other APs at early
stages of disease.
Following the successful identification of the CSF biomark-
ers t-tau, p-tau, and Aβ42 that support the clinical diagnosis
of Alzheimer’s disease, there has been a growing interest in the
discovery of similarly specific CSF biomarkers for PD and AP.
Many studies have been reported on the quantification of α-
synuclein in CSF. Although there is a general consistency that
decreased concentrations of this protein are observed in PD
and AP with α-synuclein pathology, large overlap between these
patient groups and neurological controls has hindered the intro-
duction of its quantification into clinical practice (34, 35). Sim-
ilarly, a large degree of overlap is seen for levels of oligomeric
α-synuclein and lysosomal enzyme levels in PD versus controls
(36). Yet another approach, using proteomics discovery in CSF,
did not yield a biomarker that could be applied in clinical practice
since a panel of a minimum of five proteins was required to
differentiate PD from controls at reasonable AUC (0.87) and the
AUC of single markers did not exceed 0.79 (37). Therefore, a
clinically useful CSF biomarker has not yet been identified for
PD. In contrast, however, our study supports the concept that
one (NFL) or two (NFL+ t-tau) CSF biomarkers may reliably
predict AP and PD in a population of patients with parkinsonism
at a high AUC (>0.90). This combination of biomarkers also
has a better clinical performance than the recently described
CSF biomarker UCH-L1 (38), which differentiates PD from AP
at an AUC of 0.69. In conclusion, currently the most progress
has been made in identifying CSF biomarkers for AP, with
NFL, either in combination with t-tau, being the most promising
biomarker so far.
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